HONG KONG, Mar 30, 2026 - (ACN Newswire via SeaPRwire.com) - Cryofocus Medtech (Shanghai) Co., Ltd. ("Cryofocus" or the "Company", Stock Code: 6922.HK), an innovative medical device platform company with a main focus on the field of minimally-invasive interventional cryotherapy, recently announced its annual results for the year ended December 31, 2025. The report highlights that the Company's commercialization process has comprehensively accelerated, delivering exceptional performance across core financial metrics. Alongside exponential revenue growth, Cryofocus achieved significantly improved operational efficiency and drastically narrowed losses, demonstrating its robust growth momentum and intrinsic platform value.Robust Revenue Growth, Drastically Narrowed Losses, and Continuous Improvement in Operational QualityIn 2025, Cryofocus recorded a revenue of RMB 95.27 million, representing a surging increase of 78.0% compared to RMB 53.53 million in the same period of 2024. The loss for the year was significantly narrowed by 60.0% to RMB 44.46 million, down from RMB 111.28 million in 2024, showcasing the Company's outstanding operational efficiency and cost-control capabilities.The Company's overall gross profit reached RMB 63.98 million, a year-on-year increase of 66.6%, while the gross profit margin was maintained at a healthy level of 67.2%. During the reporting period, Cryofocus continued to optimize its R&D efficiency. R&D expenses decreased by 58.6% year-on-year to RMB 30.44 million, primarily due to the reduction in investments following the successful NMPA approval of certain products, as well as the optimization of staff costs. This reflects the steady transition of the Company's R&D pipeline from an early-stage investment phase to a late-stage harvest phase.Comprehensive Acceleration of the Cryotherapy Product Matrix with Respiratory Intervention as the Core Growth Engine The strong financial growth was primarily driven by the commercial volume ramp-up of the Company's cryotherapy product pipeline, which is built upon its unique liquid nitrogen cryoablation technology and advanced flexible catheter technology platforms. Notably, the respiratory intervention product pipeline delivered a stellar performance, acting as the absolute main driving force for revenue growth.In March 2025, the Company's Malignant Stenosis Cryoablation System received approval from the National Medical Products Administration (NMPA) and was successfully commercialized in China in May of the same year, with sales volume climbing rapidly. In addition, the sales of the previously commercialized Cryoadhesion System continued to grow. Meanwhile, the Company further deepened its distribution partnership with the international medical giant Boston Scientific (BSC) in the Chinese market, which contributed considerable incremental revenue.More notably, the Company's Asthma Cryoablation System was granted designation as a "Breakthrough Medical Device" by the U.S. Food and Drug Administration (FDA) in July 2025. This marks an international authoritative recognition of its innovative technology, laying a solid foundation for its future expansion into the global market.Successful Share Placement Fortifies Financial Foundation to Facilitate Global ExpansionTo support future R&D and market expansion, the Company successfully completed the placement of new H shares to specific investors in January 2026. A total of 5,595,000 H shares were issued, raising net proceeds of approximately HK$29.73 million. Cryofocus plans to utilize the funds primarily for the R&D, manufacturing, and commercialization of minimally-invasive interventional products related to vascular intervention, respiratory intervention, and cancer intervention, as well as to provide financial backing for the potential overseas business expansion of these commercialized products.This financing not only bolstered the Company's cash reserves, securing a solid financial guarantee for the clinical development and global registration of subsequent high-value pipeline products—such as the Peri-Pulmonary Nodule Cryoablation System, COPD Cryospray System, Asthma Cryoablation System, and the Cryo-RDN System for resistant hypertension—but also underscored the strong confidence of professional institutional investors in the Company’s technology platform and long-term prospects.Looking Ahead: Platform Advantages Highlighted, Striving to Become a Global Cryotherapy LeaderLeveraging its unique "One Platform, Multiple Tracks" business model, Cryofocus has built a robust product pipeline covering multiple therapeutic areas, including vascular intervention, respiratory intervention, and cancer intervention. The Company currently possesses a comprehensive pipeline comprising 25 products and product candidates, 11 of which have already been commercialized. As more products progressively enter late-stage clinical trials and the regulatory approval phase, the value of the Company's platform is expected to be continuously unlocked.Looking ahead, Cryofocus stated that it will continue to execute its clear strategies: rapidly advancing the clinical development and commercialization of product candidates; further expanding the product portfolio based on its core technology platform; continuously investing in underlying and supporting technologies; and selectively expanding its worldwide footprint. The Company is steadily transitioning from an R&D-driven approach to a dual-engine model driven by both R&D and commercialization, taking solid steps toward its vision of becoming a "global medical device platform in the field of minimally-invasive interventional cryotherapy." Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月30日 - (亚太商讯 via SeaPRwire.com) - 专注于微创介入冷冻治疗领域的创新医疗器械平台企业——康沣生物科技（上海）股份有限公司（"康沣生物"或"公司"，股份代号：6922.HK）近日公布其截至2025年12月31日止年度的年度业绩。报告显示，公司商业化进程全面提速，核心财务指标表现卓越，全年收入实现跨越式增长，同时经营效益显著改善，亏损大幅收窄，展现出强大的成长动能与平台价值。营收高速增长，亏损大幅收窄，经营质量持续提升2025年，康沣生物实现收入人民币9526.8万元，较2024年同期的5353.1万元激增78.0%。年内亏损大幅收窄至人民币4445.6万元，较2024年同期的1.11亿元显著减少60.0%，展现出卓越的运营效率与成本控制能力。公司整体毛利达到人民币6398.4万元，同比增长66.6%。毛利率保持在67.2%的健康水平。报告期内，公司持续优化研发效率，研发开支同比减少58.6%至人民币3043.8万元，这主要得益于部分产品完成注册后相关投入减少，以及员工成本优化，反映了公司研发管线正从早期投入期向后期收获期稳步过渡。冷冻产品矩阵全面发力，呼吸介入成增长核心引擎业绩的强劲增长，主要得益于公司基于独特液氮冷冻消融技术和柔性导管技术平台打造的冷冻治疗产品线进入商业化放量阶段。其中，呼吸介入产品线表现尤为亮眼，成为驱动收入增长的绝对主力。2025年3月，公司的恶性狭窄冷冻消融系统获得中国国家药监局（NMPA）批准，并于同年5月成功商业化上市，销量迅速攀升。此外，此前已上市的冷冻粘连治疗系统销量亦持续增长。与此同时，公司与国际医疗巨头波士顿科学（波科）在中国市场的经销合作进一步深化，为公司贡献了可观的增量收入。更值得关注的是，公司的哮喘冷冻消融系统于2025年7月获得美国食品及药物管理局（FDA）授予的"突破性医疗器械"认证，标志着其创新技术获得国际权威认可，为未来进军全球市场奠定了坚实基础。成功完成新股配售，夯实资金基础助力全球拓展为支持未来研发及市场扩张，公司于2026年1月成功完成向特定投资者配售新H股。此次配售共发行5,595,000股H股，募集所得款项净额约为2973万港元。公司计划将募集资金主要用于血管介入、呼吸介入及肿瘤介入相关微创介入产品的研发、生产及商业化，以及为这些产品商业化的潜在海外业务扩张提供资金支持。此次融资不仅增强了公司的现金储备，为后续高价值在研产品（如肺周结节冷冻消融系统、慢阻肺冷冻喷雾治疗系统、哮喘冷冻消融系统及针对顽固性高血压的Cryofocus冷冻消融系统等）的临床开发和全球注册提供了坚实的资金保障，也彰显了专业投资机构对公司技术平台和长期发展前景的信心。展望未来：平台化优势凸显，迈向全球冷冻治疗领军者康沣生物凭借"一平台、多赛道"的独特商业模式，构建了涵盖血管介入、呼吸介入、肿瘤介入等多领域的强大产品管线。目前公司拥有总计25款产品组成的管线库，其中11款已实现商业化。随着更多产品陆续进入临床后期及报批阶段，公司平台价值有望持续释放。展望未来，康沣生物表示将继续执行清晰战略：迅速推动在研产品的临床开发和商业化；基于核心技术平台进一步扩大产品组合；持续投入底层技术研发；并选择性地拓展全球业务。公司正稳步从研发驱动向研发与商业化双轮驱动转型，朝着成为"全球微创介入冷冻治疗医疗器械平台"的愿景坚实迈进。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 29, 2026 - (ACN Newswire via SeaPRwire.com) - Condiments are an important carrier of Chinese culinary culture, playing an irreplaceable role in people’s daily diet, the upgrading of the catering industry, and the development of the food industry. As the absolute leader in the condiment industry, Foshan Haitian Flavouring & Food Co., Ltd. (A-share: 603288; H-share: 03288) delivered a high-quality performance report in 2025, leveraging its comprehensive product portfolio, leading digital and intelligent capabilities, and resolute internationalization strategy. The company continues to lead the industry and stands as a well-deserved industry benchmark.On 26th March, Haitian Flavouring released its 2025 annual report. Financial data shows that in 2025, the company achieved total revenue of RMB 28.873 billion, a year-on-year increase of 7.32%. Profitability improved simultaneously, with full-year net profit attributable to shareholders of the parent company reaching RMB 7.038 billion, up 10.95% year-on-year; net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses amounted to RMB 6.845 billion, a year-on-year rise of 12.81%, and the gross profit margin of its core condiment business reached 41.78%, representing a year-on-year increase of 3.15 percentage points. All operating data hit record highs, demonstrating strong development resilience and core competitiveness, and further widening the gap with industry peers.Product Matrix Diversification: Building a Foundation for Multi-Dimensional GrowthAs a time-honored Chinese enterprise with a 400-year history deeply rooted in the condiment industry, Haitian Flavouring has built a stable and resilient multi-dimensional growth pattern through its continuously enriched product portfolio for the mass market, with its core product categories maintaining a globally leading competitive position.In the soy sauce category, Haitian Flavouring has always adhered to a consumer-centric approach. Focusing on consumers’ diverse needs, the company has continuously innovated in flavor, functionality, and specifications, establishing a complete product matrix covering both basic mass consumption and various segmented scenarios. Its product lines include not only classic series, premium soy sauce series, and time-honored series for daily cooking, but also healthy and nutritious lines such as organic, less-sodium, iron-fortified, selenium-enriched, and gluten-free products, as well as trendy products such as matsutake premium soy sauce.In the oyster sauce category, the company insists on selecting premium whole oysters from high-standard marine ranches and simmering them into sauce. With genuine ingredients and rigorous craftsmanship, Haitian oyster sauce maintains its advantage of being “rich in flavor, free from any fishy taste; one simple step to seal in freshness” . Currently, the company has launched diversified products such as Haitian superior oyster sauce and golden label oyster sauce, covering different flavors, packaging specifications, and price points. In response to consumer demand, the company has carried out scenario-based innovation, successively launching new products such as spicy oyster sauce and matsutake fresh oyster sauce to continuously enrich consumer choices.In the seasoning sauce category, the company’s products are mainly divided into two categories: basic flavored sauces and compound flavored sauces. It has built a product system with rich categories, diverse flavors, and multiple scenarios, such as Chu Hou Paste, Hoisin Sauce, Sauce for Rice, and Mushroom Sauce, which are suitable for different cooking methods. Meanwhile, the company adheres to a dual-wheel layout of “traditional vinegar + specialty vinegar,” developing regional characteristic rice vinegar such as sweet rice vinegar, selected fresh rice vinegar, and kangle vinegar, as well as specialty fruit vinegar including sugar-free apple cider vinegar and raw orange vinegar. This has formed a rich and diverse vinegar product system, further consolidating the company’s all-category competitive advantages, providing solid support for its steady performance growth, and building a profound market barrier.Benefiting from the recovery of the consumer market and its extensive product portfolio, Haitian Flavouring’s core categories including soy sauce, oyster sauce, and seasoning sauces maintained steady development in 2025, achieving operating revenues of RMB 14.934 billion, RMB 4.868 billion, and RMB 2.917 billion respectively, with year-on-year growth rates of 8.55%, 5.48%, and 9.29%. The three major categories maintained positive growth simultaneously, providing solid support for the overall performance.As of the end of 2025, Haitian Flavouring has established 7 product series each generating over RMB 1 billion in revenue, and more than 30 product series each exceeding RMB 100 million, with product concentration and competitiveness continuing to improve. Among them, the two products series of Golden Label Light Soy Sauce and Mushroom Dark Soy Sauce have been bestsellers for over 60 years. The two products series of Premium Soy Sauce and Haitian Superior Oyster Sauce have achieved annual revenue of over RMB 1 billion per product for over 10 consecutive years, becoming the core drivers supporting the Company's steady performance growth and demonstrating strong product vitality and high market recognition.While consolidating its advantages in core product categories, Haitian Flavouring proactively adapts to the trend of consumption upgrading, invests heavily in new product development, creates trend-setting new products, and forms a continuously evolving growth flywheel. Supported by its industry-leading product strength, the nutritionally healthy product series, represented by organic and less-sodium options, achieved operating revenue with a year-on-year growth rate of 48.3%, significantly outperforming the industry average growth rate and opening up a new growth curve for the Company's performance growth.Furthermore, Haitian Flavouring is proactively transforming itself from a "condiments supplier" to a "comprehensive flavor solutions provider," accurately capturing the new market opportunities brought by the industrialization and chain-upgrading of the catering industry. As of the end of 2025, the Company has cumulatively provided one-stop commercial condiment solutions to catering chains, food enterprises, and numerous global retail brands, further expanding its profit margins.Meanwhile, the Company boasts leading digitalization-enabled flexible production and customized service capabilities. It can produce up to over 20 specifications and more than 130 SKUs of different products on the same production line, with its customized service response and time-to-market speed leading the industry. Powered by its digital transformation, the Company's ultimate supply chain has established a new paradigm for the collaborative development of "customization, scale, quality-to-price performance ratio" in the manufacturing industry. This not only ensures stable and safe product quality to meet the stringent requirements of chain catering but also caters to the diverse needs of different users for condiments.Digitalization Empowers Across the Entire Chain, Technological Innovation Boosts EfficiencyTechnology development and technological innovation are the core engines driving Haitian Flavouring's performance growth. The Company proactively embraces the AI era, deeply integrating artificial intelligence and big data into the entire chain of R&D, production, supply, and sales. This promotes the organic integration of cutting-edge digital technologies with millennia-old brewing techniques, achieving a comprehensive leap in production efficiency, product quality, and operational effectiveness.Every year, Haitian maintained R&D investment at approximately 3% of its operating revenue, solidifying the foundation for innovation with a long-term perspective. Meanwhile, the Company’s Gaoming production base was successfully recognized as the world's first "Lighthouse Factory" in the soy sauce brewing industry, a benchmark for smart manufacturing certified by the World Economic Forum, redefining the Digitalization height of the traditional condiments industry.With comprehensive digital empowerment, Haitian's supply chain operational efficiency has significantly improved. In 2025, the Company's On-Time In-Full (OTIF) delivery rate continued to optimize, and customer service levels reached a new height. At the same time, the ratios of manufacturing expenses and direct labor costs to operating costs-two core cost indicators- surpassed those of most peers, achieving a dual breakthrough in quality improvement, efficiency enhancement, and cost control.Thanks to its outstanding digital practices, in 2025, the Company won numerous awards, including the "CGF China Supply Chain Digitalization and Sustainable Resilience Development Case" and the "National Typical Cases of Digital Transformation in Manufacturing", establishing itself as a benchmark for digital transformation in the industry. Additionally, the national standard " General Technical Requirements for Food Production Digital Factories", led by Haitian, was officially released. This fills the gap in the field of digital factory construction in China's food industry and provides authoritative and unified technical guidelines and an implementation framework for the Digitalization upgrading of the food industry.Leveraging smart technologies, the Company also achieved notable progress in green manufacturing. In terms of energy structure, the scale of solar photovoltaic power stations increased by nearly 100%, and a biomass power generation project was also put into operation. Power generated from green energy reached 29 million kWh, while the share of green electricity exceeded 28%. Through a smart water-saving system, the Company made dedicated efforts to set a benchmark in water conservation, recycling 1.88 million cubic meters of water over the past year, equivalent to the capacity of 752 standard swimming pools. In 2025, the Company implemented 128 energy-saving and carbon-reduction initiatives, these efforts resulted in a total reduction of 29,000 tonnes of carbon dioxide equivalent, marking a solid step forward in its green and low-carbon development.Accelerating Global Expansion, Charting a New Course on the World StageWhile maintaining its leading position and deepening its presence in the domestic market, Haitian Flavouring has been proactively expanding its international footprint and accelerating its pace to "set sail" for global markets. Adhering to a dual-track development approach of "global standards + local adaptation," the Company’s products are now sold in over 80 countries and regions worldwide. It has been named a "Chinese Brand Loved by Foreigners" for two consecutive years, reflecting its growing international influence and marking a transition from "product export" to "enterprise globalization."Recently, the Company successfully upgraded its British Retail Consortium (BRC) rating from Grade B to Grade A, a testament to its quality control system receiving internationally recognized accreditation and achieving a world-class standard. This accomplishment has instilled strong confidence in the Company’s efforts to further expand its global footprint and enter premium retail channels in Europe and the United States, while also underscoring the high quality and international competitiveness of Haitian’s products.On March 17, the Company was recognized as a Leading Enterprise in the 2026 Forbes China Pioneer Innovators in Industry Development Selection in recognition of its digital and intelligent transformation as well as its green development practices, affirming the Company’s long-term value creation.In June 2025, the Company was successfully listed on the Hong Kong Stock Exchange, marking a new milestone as it now operates on the dual A+H share platform. The listing attracted eight prominent domestic and international institutions, including Hillhouse Capital and the Government of Singapore Investment Corp (GIC), to serve as cornerstone investors, underscoring the international market's recognition of the Company's growth potential and providing ample capital to support its global expansion strategy. In the same year, the Company also established its overseas production base, further enhancing its global production and sales network. This provides a solid foundation for building a global supply chain and leveraging the Company's competitive advantages from the domestic market, marking a critical step forward in the execution of its internationalization strategy.On the brand development front, the Company continues to deepen its commitment to “400-Year Legacy of Oriental Flavor” Through iconic IPs such as Chef of China, it has captured widespread attention across Mainland China, Hong Kong, Macao, Taiwan, and beyond, creating a deep resonance between traditional brewing culture and modern consumer experiences. In addition, the Company launched the “Ambassador for Chinese Flavor” Initiative, bringing together collaborators to ignite global enthusiasm for authentic Chinese cuisine.Overall, in 2025, Haitian Flavouring delivered an impressive performance, driven by its steady operations and forward-looking strategy. Building on a comprehensive product matrix and leveraging digital empowerment, the Company has successfully achieved a strategic transformation through in-depth, full-channel operations. This has enabled it to establish a core competitive edge capable of withstanding market volatility and navigating industry cycles.Looking ahead, the Company will continue to uphold its dedication to craftsmanship and innovation, further consolidate its leading position in the domestic market, and steadily accelerate its global expansion. By doing so, it aims to support the high-quality development of the traditional condiment industry, bring the taste of China to the world, and continue to lead the industry toward a new era of higher quality. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com